JP2023534793A5 - - Google Patents
Info
- Publication number
- JP2023534793A5 JP2023534793A5 JP2023501378A JP2023501378A JP2023534793A5 JP 2023534793 A5 JP2023534793 A5 JP 2023534793A5 JP 2023501378 A JP2023501378 A JP 2023501378A JP 2023501378 A JP2023501378 A JP 2023501378A JP 2023534793 A5 JP2023534793 A5 JP 2023534793A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- protein
- sequence
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063050068P | 2020-07-09 | 2020-07-09 | |
| US63/050,068 | 2020-07-09 | ||
| PCT/IB2021/056106 WO2022009123A1 (en) | 2020-07-09 | 2021-07-07 | Il-2 variants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023534793A JP2023534793A (ja) | 2023-08-14 |
| JP2023534793A5 true JP2023534793A5 (cg-RX-API-DMAC7.html) | 2024-07-16 |
| JP7819944B2 JP7819944B2 (ja) | 2026-02-25 |
Family
ID=79552299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501378A Active JP7819944B2 (ja) | 2020-07-09 | 2021-07-07 | Il-2バリアント |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230242607A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4185605A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7819944B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230037612A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115768788A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022009123A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022053864A1 (en) * | 2020-09-08 | 2022-03-17 | Kwon Byoung S | Pd-1 polypeptide variants |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN114853909A (zh) * | 2022-05-13 | 2022-08-05 | 南京吉盛澳玛生物医药有限公司 | 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088446A1 (en) * | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| CN105440123B (zh) * | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| JP6640834B2 (ja) * | 2014-08-11 | 2020-02-05 | デリニア, インコーポレイテッド | 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体 |
| WO2016100375A2 (en) * | 2014-12-15 | 2016-06-23 | Washington University | Compositions and methods for targeted cytokine delivery |
| AU2018287317B2 (en) * | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
| JP7765181B2 (ja) * | 2017-12-19 | 2025-11-06 | ゼンコア インコーポレイテッド | 改変されたil-2 fc融合タンパク質 |
| CU24554B1 (es) * | 2018-05-07 | 2021-11-04 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| US12522640B2 (en) * | 2018-07-24 | 2026-01-13 | BioNTech SE | IL2 agonists |
| CA3098930A1 (en) * | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| CN113286812B (zh) * | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| CA3117853A1 (en) * | 2018-10-29 | 2020-05-07 | 1Globe Biomedical Co., Ltd. | Novel rationally designed protein compositions |
| AU2020285636A1 (en) * | 2019-05-24 | 2021-11-04 | Proviva Therapeutics (Hong Kong) Limited | IL-2 compositions and methods of use thereof |
| EP4172216A4 (en) * | 2020-06-24 | 2024-12-04 | Medicenna Therapeutics, Inc. | BIFUNCTIONAL SUPERKINE AND USES THEREOF |
| IL304365B2 (en) * | 2021-03-31 | 2025-04-01 | Hanmi Pharmaceutical Co Ltd | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
-
2021
- 2021-07-07 JP JP2023501378A patent/JP7819944B2/ja active Active
- 2021-07-07 KR KR1020237004667A patent/KR20230037612A/ko active Pending
- 2021-07-07 EP EP21837391.8A patent/EP4185605A4/en active Pending
- 2021-07-07 US US18/004,575 patent/US20230242607A1/en not_active Abandoned
- 2021-07-07 CN CN202180048794.7A patent/CN115768788A/zh active Pending
- 2021-07-07 WO PCT/IB2021/056106 patent/WO2022009123A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shi et al. | Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment | |
| CN110872577B (zh) | 修饰的免疫细胞及其应用 | |
| Edeline et al. | CAR-T cells and BiTEs in solid tumors: challenges and perspectives | |
| US9611325B2 (en) | Construction and application of bispecific antibody HER2xCD3 | |
| EP3589308A1 (en) | Therapeutic rna | |
| WO2020037206A4 (en) | Recombinant myxoma viruses and uses thereof | |
| JP2022533957A5 (cg-RX-API-DMAC7.html) | ||
| WO2023151346A1 (zh) | 一种新型双特异性嵌合抗原受体的构建及其应用 | |
| CN110437340B (zh) | 双靶点识别可调控工程化免疫细胞的制备方法 | |
| Ma et al. | Harnessing natural killer cells for lung cancer therapy | |
| Li et al. | Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments | |
| Qian et al. | Recent advances in adoptive cell therapy for cancer immunotherapy | |
| CN110564767A (zh) | 一种减毒病毒载体系统及其在制备抗恶性肿瘤的药物中的应用及药物使用方法 | |
| CN104558192A (zh) | 一种双特异性抗体her2xcd3的构建及应用 | |
| CN115925940B (zh) | 特异性结合cd47的抗体、其重组溶瘤病毒及其用途 | |
| CN115232217B (zh) | 一种SynNotch结构及其应用 | |
| Yang et al. | Advancing liver cancer treatment with dual-targeting CAR-T therapy | |
| WO2022009123A4 (en) | Il-2 variants | |
| Zhu et al. | Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors | |
| Dash et al. | Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review | |
| EP4458862A1 (en) | Bispecific t-cell engager, recombinant oncolytic virus thereof, and use thereof | |
| CN106117367A (zh) | 一种her‑3特异性嵌合抗原受体及其应用 | |
| CN117003897B (zh) | 靶向Claudin18.2的CAR-T细胞及其用途 | |
| CN111732665B (zh) | 一种靶向表达癌胚抗原的细胞的嵌合抗原受体 | |
| CN117126290A (zh) | 双特异性抗体与nk细胞联合在治疗疾病中的应用 |